Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

NCT01583816 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: Resiquimod 0.03%
DRUG: Resiquimod 0.01%
DRUG: placebo

Sponsor

Spirig Pharma Ltd.